There are 807 resources available
3MO - Patient-reported outcomes (PROs) of Chinese patients (pts) in monarchE: Abemaciclib plus endocrine therapy (ET) in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)
Presenter: Qingyuan Zhang
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
228MO - Impact of EXTREME regimen and cetuximab, cisplatin, and paclitaxel-based regimen on clinical and humanistic outcomes in patients suffering from recurrent or metastatic head and neck squamous cell cancer
Presenter: Avinash Khadela
Session: Mini Oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
LBA11 - Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced <italic>ALK</italic>+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study
Presenter: Thanyanan Baisamut (Reungwetwattana)
Session: Mini Oral session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
21MO - Primary results of a China bridging, phase II randomized study of initial endocrine therapy (ET) ± ribociclib (RIB) in pre- & postmenopausal Chinese women with HR+/HER2– ABC
Presenter: Zhimin Shao
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
229MO - Immune checkpoint inhibitors in locally advanced and recurrent/metastatic head and neck cancer: An updated meta-analysis of phase II/III randomized controlled trials
Presenter: Kanak Parmar
Session: Mini Oral session: Head and neck cancer
Resources:
Abstract
Slides
320MO - Envonalkib vs crizotinib in treatment-naïve advanced ALK-positive NSCLC: A randomized, multicenter, phase III trial
Presenter: Wen Feng Fang
Session: Mini Oral session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
22MO - Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial
Presenter: Fei Ma
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
230MO - Pembrolizumab plus anlotinib as first-line treatment in patients of CPS≥1 with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
Presenter: Lin Gui
Session: Mini Oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 3MO, 21MO and 22MO
Presenter: Soo Chin Lee
Session: Mini Oral session: Breast cancer
Resources:
Slides
Webcast
Invited Discussant 228MO, 229MO and 230MO
Presenter: Bhumsuk Keam
Session: Mini Oral session: Head and neck cancer
Resources:
Slides
Webcast